Group 1 - In the first half of 2025, 822 out of 993 comparable ordinary stock funds achieved positive performance, representing 83% of the total [1] - The top three performing funds saw gains exceeding 60%, with 华安医药生物股票发起式A at 66.44%, 华安医药生物股票发起式C at 66.07%, and 嘉实互融精选股票A at 60.26% [1][2] - 华安医药生物股票发起式 has a cumulative return of over 68% since its inception, heavily investing in pharmaceutical companies such as 三生制药 and 信达生物 [1] Group 2 - 嘉实互融精选股票 also focuses on pharmaceutical stocks, with top holdings including 康方生物 and 百济神州, and has shown significant growth exceeding 55% in the first half of 2025 [2] - Several other pharmaceutical-themed funds, including 平安医药精选股票 and 富国医药创新股票, also reported gains over 55% [2] - Conversely, 11 ordinary stock funds experienced declines exceeding 10%, with 长信消费精选量化股票C and A dropping 12.38% and 12.20% respectively, primarily due to their focus on the consumer sector [2][3] Group 3 - The 长信消费精选量化股票 fund, which is heavily invested in the liquor sector, has seen a cumulative decline of 50% since its establishment [3] - 北信瑞丰优选成长 fund, managed by a relatively inexperienced manager, has not included any pharmaceutical stocks in its top holdings since 2022, focusing instead on liquor stocks [3] - Other funds with significant declines include 民生加银优选股票, which fell by 10.64%, and 广发高端制造股票C and A, which dropped by 10.57% and 10.39% respectively [4]

Group 1 - In the first four months of the year, 555 out of 999 comparable ordinary stock funds achieved positive performance, accounting for 55% of the total, with 25 funds rising over 20% [1] - The top-performing funds include Ping An Advanced Manufacturing Theme Stock A and C, with returns of 52.59% and 52.29% respectively [1] - The top ten holdings of the Ping An Advanced Manufacturing fund include Hengli Hydraulic, Zhejiang Rongtai, and Huashu High-Tech [1] Group 2 - The healthcare sector saw significant gains, with funds like Bank of China Health A and C, and Huaan Pharmaceutical Biotech A and C achieving returns of 41.72%, 41.53%, 40.70%, and 40.52% respectively [2] - The top holdings of the Bank of China Health fund include Heng Rui Medicine and Xin Nuo Wei [2] - The management of the Bank of China Health fund transitioned to Wang Fangzhou and Zheng Ning in March [2] Group 3 - The worst-performing fund was Guolian An Technology Power Stock, which declined by 17.45% [3] - This fund's top holdings include Hengxuan Technology and Ruixin Micro [3] - The fund is managed by veteran Pan Ming, who has extensive experience in investment management [3] Group 4 - Several funds, including Caitong Integrated Circuit Industry Stock C and GF High-end Manufacturing Stock C, suffered declines of 15.02% to 14.70% due to poor performance in the technology and new energy sectors [4] - The performance of these funds reflects broader challenges in the technology and manufacturing sectors [4] Group 5 - The top 100 stock funds by performance in the first four months show a diverse range of returns, with Ping An Advanced Manufacturing leading and several healthcare funds also performing well [5][6] - The data indicates a strong interest in healthcare and advanced manufacturing sectors among investors [5][6]

中国经济网北京5月7日讯 （记者 康博） 今年4月份，在有可比业绩的1016只普通股票型基金中，业绩 实现上涨的共有171只，另有3只持平，842只下跌。 医药与生物制药行业成为领涨板块，也让此类主题基金业绩遥遥领先。数据显示，4月份涨幅超过10% 的普通股票型基金有中银大健康股票A、中银大健康股票C、鹏华医药科技股票A、鹏华医药科技股票 C、华安医药生物股票发起式A、华安医药生物股票发起式C。 中银大健康股票A、C以12.65%、12.61%位居榜首，今年一季报显示，该基金前十大重仓股为恒瑞医药 （600276）、新诺威（300765）、百利天恒、百济神州、诺诚健华、荣昌生物、海思科（002653）、信 立泰（002294）、科伦药业（002422）、康诺亚。 汇丰晋信低碳先锋股票A、C在4月份跌幅达10.07%、10.11%，其前十大重仓股全部为新能源个股，包 括明阳智能（601615）、通威股份（600438）、隆基绿能（601012）、亿纬锂能（300014）、华友钴业 （603799）、晶澳科技（002459）、东方日升（300118）、恩捷股份（002812）、固德威、杭可科技。 值得注意的是，汇 ...